Research highlights IBS drugs offering best risk-benefit odds - ProHealth
|
Based on analysis of more than two dozen major clinical trials, two well-studied drug therapies – rifaximin and lubiprostone – offer irritable bowel syndrome (IBS) patients the best odds of benefit without harmful side effects, according to research led by the GI Motility Lab at Cedars-Sinai Medical Center in New York. ... Besides Cedars-Sinai, other centers participating in the research included the School of Medicine at Texas Tech University’s Health Sciences Center; the UCLA Department of Medicine; Beth Israel Deaconess Medical Center; and Harvard Medical School. Funding for the study was provided by the Beatrice and Samuel A. Seaver Foundation. Read the full story >> |
Related Stories
TTUHSC Names New Regional Dean for the School of Nursing
Louise Rice, DNP, RN, has been named regional dean of the TTUHSC School of Nursing on the Amarillo campus.
A Call for Change: Addressing the Invisible Workload of School-Based SLPs
Tobias Kroll, Ph.D., CCC-SLP, an Associate Professor in the Department of Speech, Language and Hearing Sciences, discusses the workloads and expectations of school-based SLPs.
Noise-Induced Hearing Loss in Rural Adolescents
Leigh Ann Reel, Au.D., Ph.D., CCC-A, discussed the causes and prevention strategies for noise-induced hearing loss, particularly for adolescents in rural areas.
Recent Stories
Collaborative Team Earns Five-Year Renewal Grant from NINDS to Continue Stroke Research
Due to this high level of productivity and potential to create new medications for stroke injury, NINDS recently awarded a new $3 million competitive renewal that extends the grant for an additional five years.
Keep Pushing: PA Alumni Gives Back
Jemimah Omavuezi, DMS, MPAS, PA-C, used her own story as inspiration to create the Omavuezi Scholarship for others.
TTUHSC Names New Regional Dean for the School of Nursing
Louise Rice, DNP, RN, has been named regional dean of the TTUHSC School of Nursing on the Amarillo campus.